HH, I believe that it's not the time to measure or calculate Revenues for any indications at this time. Patience is rewarded for those who wait for development. We can't estimate buyouts now because who knows who else will bring forth molecules or any biotechnology that can do what Leronlimab can do and those odds are increasing as the FDA continues to drag their feet or hold us back so now is not the time to say 100, 200, 500 dollars a share in 3-5 years.

Let's just take one step at a time and keep an eye on our friends but keep a closer eye on our competition til this all plays out in time. I am going to stay long and strong while not selling even a 1/2 share of my investment - GLTU HH

HCIT